PER-115-06已完成未知
A PHASE IIA, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TEST TO STUDY THE SAFETY AND EFFICACY OF MK-0822 IN PATIENTS WITH OSTEOARTHRITIS
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2007年1月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. The patient is male or female and is = 40 years old on the day they sign the informed consent.
- •2. The patient has a clinical diagnosis of osteoarthritis of the medial tibiofemoral joint of the knee for at least 6 months.
- •3. The patient belongs to functional class I, II or III of the ARA.
- •4. A patient who is potentially fertile agrees to practice abstinence or use 2 acceptable methods of birth control within the scheduled duration of the study.
- •5. The patient is willing to limit their consumption of alcohol to 14 doses per week.
- •6. The patient does not foresee a significant change in the level of strenuous physical activity during the entire study and the follow-up period.
- •7. The patient is considered to have an adequate general health condition to participate in this clinical study.
- •8. The patient knows how to read and is able to understand and complete the questionnaires and journals.
- •9. The patient understands the study procedures as well as the information of the alternative treatments available and the risks involved in the study, and voluntarily agrees to participate in the study by providing written informed consent.
- •10. The patient is ambulatory and foresees that he / she will be able to return for all the study visits within the time margins indicated in the Flow Diagram.
- •11. At Visit 1, the evaluation of the patient in terms of index knee pain when walking on a flat surface is = 30 mm or the patient is receiving medication for the treatment of OA pain of the index knee during = 15 days within the last 30 days.
排除标准
- •1. The patient suffers from a type of inflammatory arthritis in the study joint, Wilson´s disease, hemochromatosis, ochronosis, primary osteochondromatosis or fibromyalgia.
- •2. The patient is not eligible to undergo an MRI exam due to any of the following patient factors or clinical safety criteria: a) Body weight> 280 Lbs (127 kg). b) Presence of magnetic material in the organism. c) Inability to tolerate the MRI procedure. d) Inability to meet other criteria for the quality of the exam. e) Inability to meet other criteria, as determined by the MRI center for patient safety.
- •3. The patient has any of the following antecedents or conditions: a) The patient has undergone a tibial osteotomy or the replacement of any component or joint surface in the index knee. b) The patient has a history of septic arthritis or intra-articular fracture of the index knee. c) The patient has a history of acute injury of the ligaments or meniscus of the index knee within the previous 2 years. d) The patient has undergone a knee arthroscopy or surgical procedure in the lower extremities within 12 months prior to Visit 1, or has undergone hip or ankle arthroscopy or podiatric surgery within 6 months. months prior to Visit 1. e) It is expected that the patient will require a surgical or arthroscopic procedure in the lower limbs within the next 18 months. f) The patient has any other medical condition or arthritic disease that could confuse or interfere with the evaluation of efficacy.
- •4. The patient uses patellofemoral supports, lateral orthosis with wedge in the block or insoles, or assist devices for walking such as a walker, a wheelchair or two canes.
- •5. The patient has a difference = 2 cm in the length of the leg or uses custom-made shoes or prostheses that fit the differences in the length of the lower limb.
- •6. The patient is mentally or legally disabled.
- •7. The patient has a significant history or current evidence of any condition, therapy, abnormality in laboratory tests or other circumstance that could complicate the interpretation of the study results or represent an additional risk to the patient.
- •8. The patient has a history of malignant diseases = 5 years before the signing of informed consent.
- •9. The patient is pregnant or breastfeeding, or expects to conceive within the scheduled duration of the study.
- •10. The patient is currently participating or has participated in a study with a compound or device under investigation within 30 days prior to signing the informed consent or is unwilling to refrain from participating in another study.
- •11. The patient has donated blood products or has undergone a phlebotomy of> 300 mL within 8 weeks prior to signing the informed consent.
- •12. The patient is not likely to stick to the study procedures.
- •13. The patient demonstrates failure to follow the procedures required in the study.
- •14. The patient is a user of recreational or illicit drugs or has a recent history of drug or alcohol abuse or dependence.
- •15. The patient is allergic to acetaminophen / paracetamol.
- •16. The patient has a history of marked prolongation of the QT / QTc interval.
- •17. The patient has received intra-articular injections of hyaluronic acid in the lower limbs within 6 months prior to Visit 1, or anticipates needing these injections during the course of the study.
- •18. The patient has received intra-articular injections of glucocorticoids in the lower limbs within 3 month
研究者
相似试验
已完成
不适用
A PHASE IIA, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK-0773 IN PATIENTS WITH SARCOPENIAPER-065-07MERCK SHARP & DOHME PERU S.R.L.,
未知
不适用
A PHASE II RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND IMMUNOGENICITY OF V212 IN ADULT PATIENTS WITH AUTOIMMUNE DISEASEPER-031-12MERCK SHARP & DOHME PERU S.R.L.,20
招募中
3 期
“A Phase II, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of mesenchymal cells (MSV-ALLO®) in the treatment of lupus nephritis”Lupus Nephritis2024-514750-67-00Hospital Universitario Rio Hortega20
已完成
2 期
A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington’s Disease2023-509835-26-00PTC Therapeutics Inc.121
进行中（未招募）
1 期
A Phase 2A study of PTC518 in patients with Huntington's DiseaseHuntington’s diseaseMedDRA version: 20.0Level: PTClassification code 10070668Term: Huntington's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-003852-18-ATPTC Therapeutics, INC252